PDCD1 and nasopharyngeal carcinoma: We provided the combination treatment of asparaginase plus anti-PD-1 monoclonal antibody (mAb) as a compassionate therapy (Extended Data Fig. 1a) for six patients with RM-NPC, who received PD-1 therapy but still displayed progressive disease (Table 1).